---
title: "AbSci Price Target Raised to $11 as Analyst Reiterates Buy on Promising PRLR Pipeline and ABS-201 Data"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286158529.md"
description: "Analyst Debanjana Chatterjee from JonesTrading has reiterated a Buy rating on AbSci, raising the price target to $11.00 due to promising early data for ABS-201 and a favorable outlook for the AGA program. The company's strategy to expand its prolactin receptor franchise and maintain capital discipline supports long-term shareholder value. H.C. Wainwright also maintains a Buy rating with a $8.00 price target."
datetime: "2026-05-12T21:05:38.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286158529.md)
  - [en](https://longbridge.com/en/news/286158529.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286158529.md)
---

# AbSci Price Target Raised to $11 as Analyst Reiterates Buy on Promising PRLR Pipeline and ABS-201 Data

Debanjana Chatterjee, an analyst from JonesTrading, maintained the Buy rating on AbSci. The associated price target was raised to $11.00.

Debanjana Chatterjee has given his Buy rating due to a combination of factors, including encouraging early data for ABS-201 and a higher probability of success for the lead AGA program. The clean emerging safety profile, supportive pharmacokinetics, and a dosing schedule that may require just a few injections over six months underpin confidence ahead of key proof-of-concept readouts and justify raising the price target to $11.

Chatterjee also highlights AbSci’s strategy to broaden its prolactin receptor franchise with ABS-202 in immunology, while advancing ABS-201 into endometriosis and maintaining capital discipline by seeking partners for oncology assets. This focused allocation of resources toward high-return PRLR programs, combined with potential synergies across dermatology and pain indications, supports the view that the company’s pipeline can create substantial long-term shareholder value.

In another report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $8.00 price target.

### Related Stocks

- [ABSI.US](https://longbridge.com/en/quote/ABSI.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)

## Related News & Research

- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)
- [Leerink Partners Sticks to Their Buy Rating for Ibio (IBIO)](https://longbridge.com/en/news/286588262.md)
- [Analyst Reiterates Buy on Corbus, Maintains $38 Price Target on CRB-701 Oncology Potential](https://longbridge.com/en/news/286284525.md)
- [Candel Therapeutics Reports Positive Phase 3 Prostate Cancer Trial Data](https://longbridge.com/en/news/286652611.md)
- [MiNK Therapeutics' Q1 net loss narrows slightly](https://longbridge.com/en/news/286558132.md)